AC
BLCM

Armistice Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Armistice Capital’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-103,496
Closed -$1.09M – 89
2019
Q3 		$1.09M Buy
+103,496
New +$1.35M 0.07% 63

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital's BLCM Position: Q4 2019 in Review

Armistice Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2019, closing a stake of 103,496 shares — an estimated $1.09M sold.

Armistice Capital first reported a position in BLCM in Q3 2019 and held it in 1 quarter. The position peaked at $1.09M in Q3 2019. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

  • Armistice Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Armistice Capital sold 103,496 Bellicum Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1.09M.
  • Armistice Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Armistice Capital's Bellicum Pharmaceuticals, Inc. position peaked at $1.09M in Q3 2019.
  • 51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.